Maravai LifeSciences

Maravai has announced its planned acquisition of the DNA and RNA business of Officinae Bio, a provider of precision DNA and RNA design services through an AI-driven digital platform. The mRNA, Gene Editing, along with the Cell and Gene therapy markets continue to evolve rapidly, and we remain committed to being our customers’ preferred partner by delivering innovative solutions to address critical barriers, increase process efficiency and improve potency and efficacy. Read the full press release here: https://lnkd.in/g7mNN4jH #mRNA #geneediting #therapeutics #acquisition

Today we shared the latest developments at Maravai LifeSciences from our most recent earnings call, highlighting our unwavering commitment to innovation and ensuring customer success. This quarter, we commenced our first mRNA contract for a customer at our GMP manufacturing facility, further strengthened our CleanCap® IVT capping technology patent estate, and introduced a new mRNA plate-based screening offering  We remain confident in the value we provide our customers for the life-changing development of drug therapies, diagnostics, and novel vaccines. Learn more about our Q3 business highlights: https://lnkd.in/gVrzifpu The conference call webcast is available at: https://lnkd.in/gQmyuB5Y..   #miraclemakers #mRNA #lifesciences #nucleicacid

⭐ This Monday's #MiracleMaker is Destiny Hodges, a Manufacturing Associate at TriLink BioTechnologies, part of Maravai LifeSciences!   Born and raised in Arizona, Destiny graduated from the University of Arizona in Tucson with a degree in biomedical engineering. After honing her skills in laboratory research and product development, through different labs at the U of A, she moved west to San Diego to work at TriLink as a lab tech. Now she’s a manufacturing associate in the GMP mRNA manufacturing group.   Want to be a #MiracleMaker? Explore open roles below: https://lnkd.in/et6kyMar   #MiracleMakers #EmployeeSpotlight #Innovators #Innovatio

Thrilled to announce that one of our very own, Chanfeng Zhao, has been named to the 2024 PharmaVoice 100!   According to Zhao, 'mRNA’s unstoppable future is bright.' With billions of doses administered during the COVID-19 pandemic, mRNA’s safety and potential have been proven globally. The mRNA field is expanding rapidly, with over 250 cancer therapies and 500 treatments for other diseases in development. She emphasizes the importance of pushing boundaries, driven by passion and collaboration to fuel innovation.   Chanfeng - Congratulations! We are so proud to have you as part of the TriLink BioTechnologies, part of Maravai LifeSciences team.   Find the article here: https://lnkd.in/gydHwkUU   #PharmaVoice #LeadersInScience #mRNA #Biotech

⭐ This Monday's #MiracleMaker is Mark Gianino, a Quality Control Supervisor TriLink BioTechnologies, part of Maravai LifeSciences!   A former high school chemistry teacher, Mark was drawn back to industry by his love of being in the lab. He has been with the company since 2020 and after serving in a few roles of increasing responsibility, he is now a supervisor with analytical services within TriLink GMP.   Want to be a #MiracleMaker? Explore open roles below: https://lnkd.in/et6kyMar #MiracleMakers #EmployeeSpotlight #Innovators #Innovation

The Maravai LifeSciences Foundation is proud to support the Crohn's & Colitis Foundation and to celebrate the 10th annual Champions of Hope Gala.  Innovation is not just a buzzword at Maravai; it’s a way of life. We understand that the challenges to improve human health demand unprecedented solutions. Our focus on developing cutting-edge technologies that enable our customers to unlock new approaches and address unmet medical needs, combined with events like these, embody a deep dedication to driving positive change and pushing the boundaries of what’s possible. We commend the Crohn’s and Colitis Foundation for its work accelerating research, providing education, support, and advocacy programs to help find cures and improve the lives of those affected by Crohn's or Colitis. #ChampionsOfHope #CrohnsColitisFoundation #ResearchForCures

⭐ This Monday's #MiracleMaker is Lauren Edwards, a Quality Control Analytical Services Manager at TriLink BioTechnologies, part of Maravai LifeSciences!   An outdoors adventurer at heart, Lauren spends her days managing the Tech Transfer team within the Analytical Services department. With a background in analytical chemistry, she has applied her knowledge of analytical instrumentation to a variety of roles in her career.   Want to be a #MiracleMaker? Explore open roles below: https://lnkd.in/et6kyMar   #MiracleMakers #EmployeeSpotlight #Innovators #Innovation

TriLink BioTechnologies, part of Maravai LifeSciences, is excited to announce that we have expanded our Discovery mRNA synthesis services offerings with custom sets of mRNA. Our new 𝗰𝘂𝘀𝘁𝗼𝗺 𝘀𝗲𝘁𝘀 𝗼𝗳 𝗺𝗥𝗡𝗔 provide the flexibility and amount of mRNA you need for 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 (0.1 mg) and 𝗵𝗶𝘁-𝘁𝗼-𝗹𝗲𝗮𝗱 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 (0.1 to 0.5 mg). Expedite your mRNA discovery work today!   Learn more: https://lnkd.in/gMQBqeP7 #RNA #mRNAsynthesis #screening #leadoptimization #newproduct

🐾 Our finance and accounting team at Maravai LifeSciences had an amazing time volunteering with the Rancho Coastal Humane Society, assembling dog gift boxes and beds!   John Van Zante from Rancho Coastal summed it up perfectly: "This event not only helps the animals, but it also brings a sense of pride and fulfillment to everyone involved." In the midst of the ongoing shelter crisis, where so many dogs are in need of care, initiatives like these have never been more important. We're proud to support such a wonderful cause with a team building event and make a positive impact in our community!   Watch the full video at WROC-TV Channel 8: https://lnkd.in/geuf8MSt #VolunteerWork #CommunityImpact #AnimalCare #GivingBack #Teamwork

TriLink BioTechnologies, part of Maravai LifeSciences is excited to announce that we have collaborated with Alphazyme LLC to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production. The new product reduces dsRNA by up to 85%, helping to develop safer, more potent mRNA therapeutics.    Learn more: https://lnkd.in/gVDcY3Dd #RNA #announcement #mRNA #enzymes #productlaunch